PHARMACEUTICAL 2012

XOMA Royalty Corp
Rank 135 of 196



PHARMACEUTICAL 2012

XOMA Royalty Corp
Rank 135 of 196

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1.7% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 93% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	62,695
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,010
Liabilities, Non-Current	34,476
Other Assets	2,632
Other Compr. Net Income	0
Other Expenses	2,477
Other Liabilities	7,539
Other Net Income	3,689
Other Revenues	58,196
Property and Equipment	12,709
Research and Development	68,137
Selling, General and Administrative Expense	24,014

Output Variable	Value in 1000 USD
Assets	78,036
Liabilities	63,025
Expenses	94,628
Revenues	58,196
Stockholders Equity	15,011
Net Income	-32,743
Comprehensive Net Income	-32,743
BaseVar	148,787
ECR before LimitedLiability	-0.027%
Economic Capital Ratio	141%